PMID- 28293474
OWN - NLM
STAT- MEDLINE
DCOM- 20171030
LR  - 20220316
IS  - 2162-3279 (Electronic)
VI  - 7
IP  - 3
DP  - 2017 Mar
TI  - Transition from oxcarbazepine to eslicarbazepine acetate: A single center study.
PG  - e00634
LID - 10.1002/brb3.634 [doi]
LID - e00634
AB  - OBJECTIVES: There is limited clinical evidence for comparison between 
      oxcarbazepine (OXC) and eslicarbazepine acetate (ESL) in terms of tolerability, 
      or how to execute the change from OXC to ESL. We report the process of 
      transitioning patients with focal epilepsy from previous OXC treatment to ESL due 
      to tolerability problems. The rationale for change from OXC is reported, and the 
      outcome with respective to this rationale is analyzed in terms of tolerability 
      and efficacy. MATERIALS AND METHODS: The subjects were transitioned overnight 
      from OXC to ESL in a hospital inpatient setting. An evaluation of the effects of 
      the transition was made after 1 and 3 months. All adverse events (AEs) were 
      recorded following the transition period. Subjects were classified by outcome in 
      terms of AEs. RESULTS: Twenty-three subjects were transitioned from OXC to ESL. 
      Fifteen patients OXC-related AEs reduced significantly after transition. 
      Particularly, most of (93%) the AEs presented in the morning resolved after 
      transition to ESL. No patient had an increase in seizure frequency following the 
      transition. The incidence of ESL-related AEs was 39% at 1 month and 13% at 
      3 month follow-up; however, all patients continued ESL throughout the study 
      period. CONCLUSIONS: This study demonstrates that patients suffering from 
      OXC-related AEs improve in terms of tolerability after a switch to ESL with 
      maintaining seizure control. This improvement is more pronounced if the 
      OXC-related AEs are most evident following morning dosing of OXC. Transition can 
      be safely executed in an outpatient setting.
FAU - Makinen, Jussi
AU  - Makinen J
AUID- ORCID: 0000-0002-6864-3390
AD  - Department of Neurology Tampere University Hospital Tampere Finland.
FAU - Rainesalo, Sirpa
AU  - Rainesalo S
AD  - Department of Neurology Tampere University Hospital Tampere Finland.
FAU - Peltola, Jukka
AU  - Peltola J
AD  - Department of Neurology University of Tampere and Tampere University Hospital 
      Tampere Finland.
LA  - eng
PT  - Journal Article
DEP - 20170127
PL  - United States
TA  - Brain Behav
JT  - Brain and behavior
JID - 101570837
RN  - 0 (Dibenzazepines)
RN  - 0 (Voltage-Gated Sodium Channel Blockers)
RN  - 33CM23913M (Carbamazepine)
RN  - BEA68ZVB2K (eslicarbazepine acetate)
RN  - VZI5B1W380 (Oxcarbazepine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Carbamazepine/administration & dosage/adverse effects/*analogs & 
      derivatives/pharmacology
MH  - Dibenzazepines/administration & dosage/adverse effects/*pharmacology
MH  - Drug Substitution/adverse effects/*methods
MH  - Epilepsy/*drug therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Outcome Assessment, Health Care
MH  - Oxcarbazepine
MH  - *Registries
MH  - Voltage-Gated Sodium Channel Blockers/administration & dosage/adverse 
      effects/*pharmacology
MH  - Young Adult
PMC - PMC5346521
OTO - NOTNLM
OT  - epilepsy
OT  - eslicarbazepine acetate
OT  - oxcarbazepine
OT  - tolerability
OT  - treatment transition
EDAT- 2017/03/16 06:00
MHDA- 2017/10/31 06:00
PMCR- 2017/01/27
CRDT- 2017/03/16 06:00
PHST- 2016/12/02 00:00 [received]
PHST- 2016/12/12 00:00 [accepted]
PHST- 2017/03/16 06:00 [entrez]
PHST- 2017/03/16 06:00 [pubmed]
PHST- 2017/10/31 06:00 [medline]
PHST- 2017/01/27 00:00 [pmc-release]
AID - BRB3634 [pii]
AID - 10.1002/brb3.634 [doi]
PST - epublish
SO  - Brain Behav. 2017 Jan 27;7(3):e00634. doi: 10.1002/brb3.634. eCollection 2017 
      Mar.